help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 65, No. 6 1081-1087
doi:10.1210/jcem-65-6-1081
Copyright © 1987 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KNUTH, U. A.
Right arrow Articles by NIESCHLAG, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KNUTH, U. A.
Right arrow Articles by NIESCHLAG, E.

Treatment of Severe Oligospermia with Human Chorionic Gonadotropin/Human Menopausal Gonadotropin: A Placebo-Controlled, Double Blind Trial

ULRICH A. KNUTH, WERNER HÖNIGL, MONIKA BALS-PRATSCH, GUNTER SCHLEICHER and EBERHARD NIESCHLAG*

Max Planck Clinical Research Unit for Reproductive Medicine and Institute of Reproductive Medicine of the University Steinfurter Str. 107, 4400 Münster, West Germany

In an effort to evaluate the effect of hCG/human menopausal gonadotropin (hMG) treatment on semen parameters in normogonadotropic men suffering from oligospermia, a double blind, placebo-controlled study was conducted. After 2 basal examinations of seminal parameters and reproductive hormones, 39 men were recruited for the trial. Nineteen men, allocated randomly to the active drug group, received im injections of 2500 IU hCG twice a week in combination with 150 IU hMG three times a week for 13 weeks, while 20 men were treated, following the same injection schedule, with NaCl only. After the 13-week treatment period, follow-up examination was performed, followed by 3 additional examinations at 4-week intervals. Of those men receiving hCG-hMG, 2 induced pregnancies in their wives, while no pregnancies were reported in the placebo group. Sperm concentrations, the percentages of motile sperm, and the proportions of normally formed spermatozoa, however, were similar in the 2 groups at all times. It was not possible to predict the outcome of treatment based on results of GnRH and hCG tests performed before the treatment phase.

* To whom requests for reprints should be addressed.

Received April 21, 1987.




This article has been cited by other articles:


Home page
J AndrolHome page
D. Madhukar and S. Rajender
Hormonal Treatment of Male Infertility: Promises and Pitfalls
J Androl, March 1, 2009; 30(2): 95 - 112.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, S. M. Wishart, and D. J. Handelsman
A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Recombinant Human Chorionic Gonadotropin on Muscle Strength and Physical Function and Activity in Older Men with Partial Age-Related Androgen Deficiency
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3125 - 3135.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1987 by The Endocrine Society